Cavitation Technologies, Inc. (CTi), a leader in nano-technology systems for fluid processing, has made a strategic move by selling certain patents and trademarks to Desmet Group, SA, for approximately $1.5 million. This transaction, comprising $1.1 million in cash and the forgiveness of about $400,000 in advances, allows CTi to retain exclusive licenses for using the technology in water and wastewater processing, as well as in the alcoholic beverage industry. This strategic decision underscores CTi's focus on leveraging its technology in the burgeoning water treatment sector.
The deal is pivotal for CTi, as it provides the necessary capital to sustain operations and explore new business avenues without resorting to potentially harmful financing options. Neil Voloshin, CTi's CEO, highlighted the transaction's importance in securing the company's financial stability and enabling its strategic pivot towards water treatment opportunities. With a market valuation of around $3 million in 2024, this infusion of capital is timely for CTi to pursue its ambitions in water remediation and treatment technologies.
CTi's technology stands out for its chemical-free water remediation capabilities, ease of integration into existing processes, and energy efficiency. The company has already made strides by installing a system at a major water remediation company in Texas and is targeting additional clients in the Permian Basin. Furthermore, CTi is testing its water treatment system at Hacienda Farms in Canada, aiming to enhance water quality for agricultural use by increasing oxygen levels and controlling bacterial growth without harsh chemicals.
Innovation remains at the core of CTi's strategy, with the development of HydroPlasma, a novel technology combining cavitation and cold plasma for more efficient water treatment. Partnerships with academic institutions are underway to refine and test these advancements. The global water treatment market, valued at approximately $2.51 billion in Canada alone, alongside the projected growth of the cold plasma market to $3.1 billion by 2027, presents significant opportunities for CTi.
Despite the challenges inherent to being a small technology firm, CTi's strategic redirection towards water treatment and its commitment to innovation position it to potentially tap into the increasing global demand for sustainable water solutions. This move not only aims to enhance shareholder value but also contributes to addressing critical environmental challenges through advanced technology.
